The interaction between the endocannabinoid system and catecholaminergic circuits has gained increasing attention as it is recognized that the development of synthetic cannabinoid receptor agonists/antagonists or compounds targeting endocannabinoid synthesis/metabolism may hold some therapeutic potential for the treatment of psychiatric disorders. The noradrenergic system plays a critical role in the modulation of emotional state, primarily related to anxiety, arousal, and stress. Recent evidence suggests that the endocannabinoid system mediates stress responses and emotional homeostasis, in part, by targeting noradrenergic circuits. This review summarizes our current knowledge regarding the anatomical substrates underlying regulation of noradrenergic circuitry by the endocannabinoid system. It then presents biochemical evidence showing an important effect of cannabinoid modulation on adrenergic receptor signaling. Finally, new evidence from behavioral pharmacology studies is provided demonstrating that norepinephrine is a critical determinant of cannabinoid-induced aversion, adding another dimension to how central noradrenergic circuitry is regulated by the cannabinoid system.
Introduction
For centuries, cannabis preparations have been used for their medicinal properties. However, psychotropic and mood altering properties are common and cannabis users have described "visions of devils" and "communication with spirits" (Zuardi, 2006) . In the Western world, the use of cannabis for therapeutic purposes did not reach prominence primarily due to difficulties in obtaining reproducible effects in clinical studies, and because of the development of more effective medications. However, cannabis has been, and still is, used for recreational purposes and is exploited for its euphoric and sedative properties. Nevertheless, adverse effects, such as anxiety, panic and depression, are also commonly reported (Johns, 2001) .
A link between cannabis use and the development of serious mental illnesses, including schizophrenia, bipolar disease and major depression, has been debated for several decades (Degenhardt et al., 2003; Johns, 2001; Strakowski et al., 2007; van Rossum et al., 2009) . It is still not clear whether cannabis use can trigger or facilitate the onset of a psychiatric disorder or whether the genetic predisposition for mental illness leads to consumption of cannabis to compensate for any disturbance in the endocannabinoid system. In summary, there is a significant amount of evidence implicating the endocannabinoid system in psychiatric disorders (Degenhardt et al., 2003; Fernandez-Espejo et al., 2009; Parolaro et al., 2010; Viveros et al., 2005) . Considering that the monoamine system is critically involved in the pathophysiology of depression, anxiety and post-traumatic stress disorder (PTSD), the goal of the present review is to explore the association between the endocannabinoid and noradrenergic systems with a particular emphasis on the pathophysiology of psychiatric disorders.
Cannabinoids, norepinephrine and mood regulation
There are a number of contradictory reports in the literature regarding the effects of cannabinoids on mood. For example, both cannabinoid type 1 receptor (CB1r) agonists (Gobbi et al., 2005; Hill and Gorzalka, 2005; Morrish et al., 2009 ) and antagonists (Griebel et al., 2005; Shearman et al., 2003; Tzavara et al., 2003) have been shown to exert an antidepressant-like effect in pre-clinical animal studies. Furthermore, cannabinoid receptor agonists/antagonists have been shown to exert anxiolytic effects in some studies but anxiogenic effects in others (Carvalho et al., 2010b; Degroot, 2008 
